The Global Oral Thin Film Drugs Market is expected to display very high growth in forthcoming period. The thin films have gained wide acceptance globally and countries such as North America and Europe have registered increasing sales contributing significantly to the market share and growth of oral thin film drugs market in the region.
Thin film drugs are the preferred option in treatment of schizophrenia, migraine, opioid dependence and nausea and vomiting contributing to desired therapeutic results. Hence oral thin film drugs market is expected to witness an exponential growth. Thin films are dispersible merging with the systemic circulation of the body immediately and hence veritably better than tablets or capsules. Lower development costs, lower cost of final drug and increasing efforts in direction of R&D are slated to increase growth of the market.
Thin films are foreseeing higher therapeutic results in oral thin film drugs market sales over sales by traditional drugs enhancing favorable market growth in the industry. Reversibly, growth in this market is hampered by high costs associated with treatment. Tracking a rising global demand for oral thin film drugs, research and development (R&D) is not far behind with 10 such prescription products and 29 thin film products under clinical investigations foreseeing extreme high growth for oral thin film drug market.
Segmentation of oral thin film drugs industry by product type includes oral thin films, transdermal thin films and others. Oral Thin films are segmented into sublingual film and fully dissolving dental / buccal film and transdermal thin film. By disease indication, oral thin films are segmented into schizophrenia, migraine, opioid dependence and nausea and vomiting.
By geographical regions, the market is segmented into North America, Europe, Asia pacific, MEA and Latin America. Oral thin films are slated to post profound growth in markets over contemporary transdermal films keeping in sight number of clinical trials and prescription products in market. Transdermal films are projected to portray high growth at the end of the forecast period.
US alone accounted for more than 3/ 4th market growth in oral thin film drug market and this market success is due to conducive factors such as technological impetus in pharmaceutical drug delivery and innovative drug delivery. Though markets in Europe are saturated with oral thin films drug, the market is lively in Asia Pacific with India, China and Japan displaying huge market growth.
Latest product launches and favorable government rules and complete knowledge regarding oral thin film drug are expected to drive market growth. The key players in the oral thin film drugs market include Pfizer, Inc., Novartis AG, WOlrtersKluver, Solvay, Allergian Plc, SummitomoDainnipon Pharma Company Limited, and Intel GenX Corp.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Oral Thin Film Drugs in these regions, from 2013 to 2025 (forecast), covering
• North America
• Southeast Asia
Global Oral Thin Film Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Sumitomo Dainippon Pharma Co., Ltd.
• Pfizer, Inc.
• Novartis AG
• ZIM Laboratories Limited
• Indivior Plc.
• Allergan Plc.
• IntelGenx Corp
• NAL Pharma
• Wolters Kluwer
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Sublingual Film
• Fully Dissolving Dental/Buccal Film
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Opioid Dependence
• Nausea & Vomiting
Research Support Specialist, USA